UNLABELLED: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious adverse drug reaction. We conducted a genomewide association study to search for genetic variants with a large effect size that increase the risk for BRONJ. METHODS: We ascertained BRONJ cases according to the diagnostic criteria of the American Association of Oral and Maxillofacial Surgeons. We genotyped cases and a set of treatment-matched controls using Illumina Human Omni Express 12v1 chip (733,202 markers). To maximize the power of the study, we expanded the initial control set by including population and treatment-tolerant controls from publicly available sources. Imputation at the whole-genome level was performed to increase the number of single nucleotide polymorphisms (SNPs) investigated. Tests of association were carried out by logistic regression, adjusting for population structure. We also examined a list of candidate genes comprising genes potentially involved in the pathogenesis of BRONJ and genes related to drug absorption, distribution, metabolism, and excretion. RESULTS: Based on principal component analysis, we initially analyzed 30 white cases and 17 treatment-tolerant controls. We subsequently expanded the control set to include 60 genetically matched controls per case. Association testing identified a significant marker in the RBMS3 gene, rs17024608 (p-value < 7 × 10(-8)); individuals positive for the SNP were 5.8× more likely to develop BRONJ (odds ratio, 5.8; 95% confidence interval, 3.1-11.1). Candidate gene analysis further identified SNPs in IGFBP7 and ABCC4 as potentially implicated in BRONJ risk. CONCLUSION: Our findings suggest that genetic susceptibility plays a role in the pathophysiology of BRONJ, with RBMS3 having a significant effect in the risk.
UNLABELLED: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious adverse drug reaction. We conducted a genomewide association study to search for genetic variants with a large effect size that increase the risk for BRONJ. METHODS: We ascertained BRONJ cases according to the diagnostic criteria of the American Association of Oral and Maxillofacial Surgeons. We genotyped cases and a set of treatment-matched controls using Illumina Human Omni Express 12v1 chip (733,202 markers). To maximize the power of the study, we expanded the initial control set by including population and treatment-tolerant controls from publicly available sources. Imputation at the whole-genome level was performed to increase the number of single nucleotide polymorphisms (SNPs) investigated. Tests of association were carried out by logistic regression, adjusting for population structure. We also examined a list of candidate genes comprising genes potentially involved in the pathogenesis of BRONJ and genes related to drug absorption, distribution, metabolism, and excretion. RESULTS: Based on principal component analysis, we initially analyzed 30 white cases and 17 treatment-tolerant controls. We subsequently expanded the control set to include 60 genetically matched controls per case. Association testing identified a significant marker in the RBMS3 gene, rs17024608 (p-value < 7 × 10(-8)); individuals positive for the SNP were 5.8× more likely to develop BRONJ (odds ratio, 5.8; 95% confidence interval, 3.1-11.1). Candidate gene analysis further identified SNPs in IGFBP7 and ABCC4 as potentially implicated in BRONJ risk. CONCLUSION: Our findings suggest that genetic susceptibility plays a role in the pathophysiology of BRONJ, with RBMS3 having a significant effect in the risk.
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Kai Wang; Mingyao Li; Dexter Hadley; Rui Liu; Joseph Glessner; Struan F A Grant; Hakon Hakonarson; Maja Bucan Journal: Genome Res Date: 2007-10-05 Impact factor: 9.043
Authors: Anna C Need; Dongliang Ge; Michael E Weale; Jessica Maia; Sheng Feng; Erin L Heinzen; Kevin V Shianna; Woohyun Yoon; Dalia Kasperaviciūte; Massimo Gennarelli; Warren J Strittmatter; Cristian Bonvicini; Giuseppe Rossi; Karu Jayathilake; Philip A Cola; Joseph P McEvoy; Richard S E Keefe; Elizabeth M C Fisher; Pamela L St Jean; Ina Giegling; Annette M Hartmann; Hans-Jürgen Möller; Andreas Ruppert; Gillian Fraser; Caroline Crombie; Lefkos T Middleton; David St Clair; Allen D Roses; Pierandrea Muglia; Clyde Francks; Dan Rujescu; Herbert Y Meltzer; David B Goldstein Journal: PLoS Genet Date: 2009-02-06 Impact factor: 5.917
Authors: Si-Huei Lee; Rai-Chi Chan; Shy-Shin Chang; Yin-Ling Tan; Kai-Hsiang Chang; Matthew C Lee; Huai-En Chang; Chien-Chang Lee Journal: Support Care Cancer Date: 2013-11-08 Impact factor: 3.603
Authors: Parish P Sedghizadeh; Allan C Jones; Chris LaVallee; Roger W Jelliffe; Anh D Le; Peter Lee; Andrew Kiss; Michael Neely Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Date: 2012-12-12
Authors: Guang Yang; Joseph M Collins; Roya Rafiee; Sonal Singh; Taimour Langaee; Caitrin W McDonough; L Shannon Holliday; Danxin Wang; Jatinder K Lamba; Young Sick Kim; Gian Andrea Pelliccioni; Mihaly Vaszilko; Janos P Kosa; Bernadett Balla; Peter A Lakatos; Joseph Katz; Jan Moreb; Yan Gong Journal: J Bone Miner Res Date: 2020-10-23 Impact factor: 6.741